Hybridoma technology is the technology of forming a hybrid cell line (hybridoma) by combining specific antibody-producing B cells with myeloma cells (cancer B cells), due to their ability to grow in tissue culture and lack of chain synthesis, antibodies. The antibodies produced by hybridomas are specific and are therefore monoclonal antibodies. To get more information on custom made antibodies visit https://www.bosterbio.com/services/custom-antibody-production-services.
Companies like BosterBio offers a complete range of speciality polyclonal and monoclonal antibody creation services from peptide synthesis or gene expression to antibody labelling and purification. We have the capacity to produce antibodies in research or on a large scale for the diagnostic industry.
The companies peptide synthesis, predict epitope, protein expression, monoclonal or polyclonal antibody production and antibody purification from ascitic fluid, cell cultures, or whole serum. They also produce monospecific polyclonal antibodies by ligand affinity chromatography.
Companies like Bosterbio has established a standard surgical procedure for the selective identification of antibodies that bind not only immunogens but also relevant target antigens in ELISA, immunoprecipitation, Western blotting, immunofluorescence, and immunohistochemistry. Often, polyclonal or monoclonal antibodies generated with recombinant proteins and peptides cannot recognize target antigens (eg protein antigens in tissue) and are essentially useless.
To generate antibodies that recognize natural antigens, they use or predict the 3-D structure of the target protein and design a peptide immunogen that appears on the protein surface and contains a linear continuous epitope.
When recombinant protein immunogens are used, they are usually expressed in a soluble form to extract the immunogenic properties of their natural analogues.